Saxonov Serge's Form 4 filing
10x Genomics, Inc. (TXG) · filed Sep 24, 2026
- Accession no.
- 0001610717-26-000421
- Filed
- Sep 24, 2026, 4:29 PM ET
- Trade date
- Sep 22, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions. Open-market sales total $2.03M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Saxonov SergeCIK 0001786720 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Class A Common Stock | SSaleDisposed | −1,000 | $78.23F2 | −$78,228.4 | 1,074,249 | Direct | |
| Sep 22, 2026 | Class A Common Stock | SSaleDisposed | −2,000 | $79.62F3 | −$159,239 | 1,072,249 | Direct | |
| Sep 22, 2026 | Class A Common Stock | SSaleDisposed | −9,300 | $80.90F4 | −$752,400.69 | 1,062,949 | Direct | |
| Sep 22, 2026 | Class A Common Stock | SSaleDisposed | −9,900 | $81.83F5 | −$810,071.46 | 1,053,049 | Direct | |
| Sep 22, 2026 | Class A Common Stock | SSaleDisposed | −2,800 | $82.37F6 | −$230,622 | 1,050,249 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.